Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Operating Leases (2023 - 2025)

CG Oncology filings provide 3 years of Operating Leases readings, the most recent being $3.1 million for Q4 2025.

  • On a quarterly basis, Operating Leases rose 5873.08% to $3.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.1 million, a 5873.08% increase, with the full-year FY2025 number at $3.1 million, up 5873.08% from a year prior.
  • Operating Leases hit $3.1 million in Q4 2025 for CG Oncology, down from $3.3 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $3.3 million in Q3 2025 to a low of $52000.0 in Q4 2024.
  • Median Operating Leases over the past 3 years was $244000.0 (2023), compared with a mean of $954555.6.
  • Biggest five-year swings in Operating Leases: plummeted 78.69% in 2024 and later surged 5873.08% in 2025.
  • CG Oncology's Operating Leases stood at $244000.0 in 2023, then plummeted by 78.69% to $52000.0 in 2024, then surged by 5873.08% to $3.1 million in 2025.
  • The last three reported values for Operating Leases were $3.1 million (Q4 2025), $3.3 million (Q3 2025), and $706000.0 (Q2 2025) per Business Quant data.